New & Noteworthy

Jan 29, 2018
Outlining the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Jan 26, 2018
Pharmaceutical Executive
In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.
Jan 18, 2018
Rachel Howard makes the case for pharmaceutical companies to include the developing world front and centre in their vision.
Jan 12, 2018
Pharmaceutical Executive
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.
Jan 11, 2018
mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.
Jan 11, 2018
Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.
Jan 11, 2018
Pharmaceutical Executive
States will continue to press for price controls, while FDA will tackle opioids and promote innovation.
Jan 09, 2018
Pharmaceutical Executive
Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
Jan 02, 2018
For the pharma sector across Europe, Brexit is just one of the tough issues to think about in 2018, writes Reflector.
Dec 31, 2017
Enacting landmark tax reform legislation that makes major changes in the corporate tax structure was Congress's Christmas present to President Trump — and to industry, writes Jill Wechsler.
native1_300x100
lorem ipsum